UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8‑K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  March 17, 2016

 

 

GlycoMimetics, Inc.

(Exact name of registrant as specified in its charter)

 

 

9708 Medical Center Drive

Rockville, MD 20850 

(Address of principal executive offices, including zip code)

 

(240) 243-1201

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 17, 2016, the Board of Directors (the “Board”) of GlycoMimetics, Inc. (the “Company”) appointed Mr. Daniel M. Junius to serve as a director of the Company and a member of the Audit Committee of the Board.  Mr. Junius will serve as a Class I director whose term will expire at the 2018 annual meeting of stockholders.  There is no arrangement or understanding between Mr. Junius and any other person pursuant to which he was selected as a director of the Company, and there is no family relationship between Mr. Junius and any of the Company’s other directors or executive officers.  The Company is not aware of any transaction involving Mr. Junius requiring disclosure under Item 404(a) of Regulation S-K. Additional information about Mr. Junius is set forth below.

 

Daniel M. Junius, age 63, has served as a member of our Board since March 2016.  Mr. Junius has served as President and Chief Executive Officer of ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics, since January 2009. Prior to that, he served as President and Chief Operating Officer and Acting Chief Financial Officer of ImmunoGen from July 2008 to December 2008, as Executive Vice President and Chief Financial Officer from 2006 to July 2008, and as Senior Vice President and Chief Financial Officer from 2005 to 2006. Mr. Junius has also served as a director of ImmunoGen since November 2008. Before joining ImmunoGen, Mr. Junius was Executive Vice President and Chief Financial Officer of New England Business Service, Inc. (NEBS), a business-to-business direct marketing company, from 2002 until its acquisition by Deluxe Corporation in 2004 and Senior Vice President and Chief Financial Officer of NEBS from 1998 to 2002. Prior to NEBS, he was Vice President and Chief Financial Officer of Nashua Corporation, a manufacturer and marketer of specialty imaging paper and label products and services. He joined Nashua Corporation in 1984 and held financial management positions of increasing responsibility before becoming Chief Financial Officer of that company in 1996. Mr. Junius holds a Bachelor of Arts in Political Science from Boston College and a Master’s in Management from Northwestern University’s Kellogg School of Management.

In accordance with the Company’s compensation policy for non-employee directors, upon his appointment as a director, Mr. Junius was granted a nonqualified stock option to purchase 22,000 shares of the Company’s common stock at an exercise price of $5.99, the closing price of the Company’s common stock on the date of grant.  This option will vest and become exercisable in three equal installments on the first, second and third anniversaries of the date of grant subject to Mr. Junius’s Continuous Service (as defined in the Company’s 2013 Equity Incentive Plan) through such vesting periods.  Additionally, Mr. Junius will be entitled to receive a $35,000 annual retainer for his service as director and a $7,500 annual retainer for his service on the Audit Committee.  At each annual stockholder meeting following which Mr. Junius’s term as a director continues, Mr. Junius will be entitled to receive an additional nonqualified stock option to purchase 11,000 shares of the Company’s common stock, which option will vest and become exercisable over a one-year period following the date of grant.  Mr. Junius has also entered into the Company’s standard form of indemnification agreement.    

 

 

Item 7.01             Regulation FD Disclosure.

 

On March 21, 2016, the Company issued a press release announcing Mr. Junius’s appointment to the Board.  A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report. The information contained in the press release furnished as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

 

 

Item 9.01 Exhibits. 

 

(d) Exhibits

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EXHIBIT INDEX

 

Exhibit 99.1

 

 

 

GLYCOMIMETICS APPOINTS IMMUNOGEN CEO Daniel Junius 

TO BOARD OF DIRECTORS

 

Gaithersburg, MD, March 21, 2016 –  GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Daniel Junius to its Board of Directors. Mr. Junius is President and Chief Executive Officer and a member of the board of directors of ImmunoGen, Inc., an industry leader in the field of antibody drug conjugates (ADCs).  He also serves on the Board of Directors of IDEXX Laboratories, a leading provider of diagnostic and information technology-based products and services for pet healthcare innovation.

“A seasoned biopharmaceutical industry executive with years of experience in financial and leadership roles, Daniel is a great addition to the GlycoMimetics Board of Directors,” said Rachel King, CEO of GlycoMimetics. “I have no doubt that as CEO of a company using ADC technology to develop novel cancer therapies he will be an asset to GlycoMimetics as we advance our clinical pipeline, particularly our own programs in oncology.”

Mr. Junius was promoted to President and Chief Operating Officer of ImmunoGen in July 2008 and became President and Chief Executive Officer of the company in 2009. He joined ImmunoGen as Chief Financial Officer (CFO) and Senior Vice President, Finance in May 2005 and was promoted to Executive Vice President, Finance and CFO in July 2006.

Mr. Junius was Executive Vice President and CFO of New England Business Service, Inc. (NEBS) from 2002 until its acquisition by Deluxe Corporation in 2004 and Senior Vice President and CFO of NEBS from 1998 to 2002. Prior to NEBS, he was Vice President and CFO of Nashua Corporation. He joined Nashua Corporation in 1984 and held financial management positions of increasing responsibility before becoming CFO in 1996. Mr. Junius holds a Master’s in Management from Northwestern University's Kellogg School of Management.

“There remain so many critical unmet needs in the treatment of individuals living with various cancers,” said Mr. Junius. “I look forward to working with the Board and management team at GlycoMimetics during the next phase of the company’s advancement, particularly as the oncology pipeline programs move into and through clinical development.”

About GlycoMimetics, Inc.

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics entered into an exclusive license agreement with Pfizer for rivipansel in October 2011. Under the license agreement, Pfizer is responsible for the clinical development, regulatory approval and potential commercialization of rivipansel, which is currently being evaluated in a Phase 3 study for treatment of vaso-occlusive crisis of sickle cell disease.

GlycoMimetics’s wholly-owned drug candidate (GMI-1271) for AML and other blood disorders is also in clinical trials. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Learn more at www.glycomimetics.com.

# # #

Source: GlycoMimetics

 

Investor Contact:

Shari Annes

Phone: 650-888-0902

Email: sannes@annesassociates.com

 

Media Contact:

Jamie Lacey-Moreira

Phone: 410-299-3310

Email: jamielacey@presscommpr.com